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Abstract
Given that prolonged exposure to estrogen and increased telomerase activity are associated with endometrial
carcinogenesis, our objective was to evaluate the interaction between the MAPK pathway and estrogen induction of
telomerase activity in endometrial cancer cells. Estradiol (E2) induced telomerase activity and hTERT mRNA expression in the
estrogen receptor (ER)-a positive, Ishikawa endometrial cancer cell line. UO126, a highly selective inhibitor of MEK1/MEK2,
inhibited telomerase activity and hTERT mRNA expression induced by E2. Similar results were also found after transfection
with ERK 1/2-specific siRNA. Treatment with E2 resulted in rapid phosphorylation of p44/42 MAPK and increased MAPK
activity which was abolished by UO126. The hTERT promoter contains two estrogen response elements (EREs), and
luciferase assays demonstrate that these EREs are activated by E2. Exposure to UO126 or ERK 1/2-specific siRNA in
combination with E2 counteracted the stimulatory effect of E2 on luciferase activity from these EREs. These findings suggest
that E2-induction of telomerase activity is mediated via the MAPK pathway in human endometrial cancer cells.
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Introduction
Endometrial cancer is the most most common malignancy in
women in the United States [1]. Endogenous and exogenous
estrogen exposure are major risk factors for the development of
type I endometrial cancers; however, the molecular link between
estrogen and endometrial carcinogenesis remains poorly under-
stood. Our previous work demonstrated that estrogen regulation of
telomerase may potentially play a role in the malignant
transformation of the endometrium [2].
Telomeres are specialized structures of the distal end of
chromosomes and function in chromosome protection, position-
ing, and replication. With aging, human telomeres inevitably
undergo progressive shortening in normal somatic cells through
the replication-dependent sequence loss at terminal ends of the
DNA. The progressive shortening of telomeres eventually results
in chromosomal instability, leading to cellular senescence.
Telomerase is a ribonucleoprotein reverse transcriptase that
synthesizes telomeric DNA into chromosomal ends. This enzyme
recognizes the G-rich strand of an existing telomere repeat
sequence and synthesizes a new copy of the repeat sequence in the
absence of a complementary DNA strand, with a segment of its
internal RNA component serving as a template [3,4]. Thus,
telomerase is comprised of an RNA template (human telomerase
RNA, hTR) and the catalytic protein hTERT (human telomerase
reverse transcriptase, hTERT) which has reverse transcriptase
activity [5–7]. The expression of hTERT is observed at high levels
in telomerase-positive cancer cells but not in telomerase-negative
cells, and is considered the rate-limiting determinant of telomerase
activity [7,8].
More than 85% of human endometrial carcinomas express
telomerase activity [9–12], and the level of telomerase activity has
been correlated with advanced stage disease and with pelvic lymph
node metastasis [12]. The human endometrium is a uniquely
dynamic tissue, consisting of epithelial glands and connective tissue
that undergoes complex patterns of proliferation, secretion, and
breakdown throughout the reproductive years. During the
menstrual cycle, endometrial epithelial cells are regulated by the
sex hormones estrogen and progesterone, and endometrial
carcionogenesis is thought to be associated with prolonged
exposure to estrogen, unopposed by progesterone. In the normal
endometrium, expression of telomerase is correlated with cellular
proliferation, is typically localized in epithelial glandular cells, and
is regulated in a hormonally-driven, menstrual phase-dependent
manner [13,14]. Increased telomerase activity is observed in the
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proliferative phase when estrogen levels are maximal followed by
near absent levels in the secretory phase when progesterone levels
are high [13]. Such evidence suggests a relationship between sex
steroid levels, the modulation of telomerase activity and the
development of endometrial cancer.
The promoter region of hTERT has been cloned and
characterized and contains two putative estrogen response
elements (EREs), implying a direct linkage between estrogen and
telomerase regulation [2,15–18]. We have previously found that
telomerase activity and hTERT mRNA were increased in
response to estrogen in an estrogen receptor-a (ERa) dependent
fashion in endometrial cancer cell lines [2]. Furthermore, we
demonstrated binding of complexed estrogen with ERa to the
EREs found within the hTERT promoter, indicative of a possible
underlying mechanism between telomerase induction and the
malignant transformation of hormone-dependent endometrial
cells [2].
Mitogen-activated protein kinases (MAPK) are an important
family of protein kinases involved in transmitting signals from the
cell membrane to the nucleus. It is well known that the p44/42
MAPK signaling pathway is activated by mitogenic stimuli from
growth factors and sex steroid hormones such as estrogen,
progesterone, and epidermal growth factor (EGF) in human
breast, ovarian and endometrial cancer cells, among others [19–
21]. In order to gain insight into the molecular mechanisms that
control the regulation of telomerase activity by estrogen, we
examined the relationship between the MAPK pathway and
estrogen-induced telomerase activity in human endometrial cancer
cells.
Materials and Methods
Cell Culture and Reagents
The regulation of telomerase expression was investigated in ER-
positive (Ishikawa) and ER-negative (HEC-1B) human endome-
trial cancer cell lines [22,23]. These cell lines were provided as gift
by Dr. Bruce Lessey (Center for Women’s Medicine, Greenville,
SC). As previously described, estrogen-induced ERE chloram-
phenicol acetyltransferase (CAT) activity was determined in each
of these cell lines to confirm functional ER status [24]. Ishikawa
and HEC-1B cells were grown in MEM supplemented with 5%
fetal bovine serum (FBS), 100 units/ml penicillin and 100 mg/ml
streptomycin in the presence 5% CO2 at 37uC. The endometrial
cancer cell lines were cultured in phenol-red free medium with
0.5% charcoal-dextran-treated FBS for 1 day before treatment
with estrogen or U0126.
Chemicals and plasmid
All hTERT reporter promoter luciferase plasmids were
provided by Dr. I. Horikawa (National Institute of Health,
Bethesda, MD). 17-b estradiol (E2) was purchased from Sigma (St.
Louis, MO). UO126 was purchased from Calbiochem (La Jolla,
CA). The anti-phosphorylated p42/44 and anti-nonphosphory-
lated p42/44 antibodies were from Cell Signaling Technology
(Beverly, MA). The anti-b-actin antibody was from Santa Cruz
Biotechnology (Santa Cruz, CA). The enhanced chemilumines-
cence Western blotting detection reagents were from Amersham
(Arlington Heights, IL). All other chemicals were from Sigma (St.
Louis, MO).
E2 and U0126 Treatment
Cells were seeded at 46105 cells per T25 culture flask or
1.56105 cells per well of a 12-well plate, containing either 5 ml or
1.2 ml regular medium, respectively. The media was then
changed to phenol-red free medium with 0.5% stripped FBS
for incubation at 37uC overnight. Immediately prior to
treatment, the medium in the culture plates was aspirated, triply
washed with phosphate-buffered saline (PBS) and replaced with
fresh medium. E2 dissolved in ethyl alcohol or U0126 dissolved in
DMSO was subsequently added to each well. Concurrently, the
same amount of ethyl alcohol or DMSO was added to the control
wells.
Telomerase Activity Assay
Telomerase activity was measured using a PCR-based telomeric
repeat amplification protocol (TRAP) (TRAP-eze telomerase
detection kit, oncor, Gaithersburg, MA). Briefly, cell pellets were
lysed, homogenized with 105 uL of ice-cold 16 CHAPS, put on
ice for 30 min, and centrifuged at 13000 g for 21 min at 4uC. The
resulting supernatent was then transferred into a fresh tube and
stored at 280uC. A sample from the extract was then taken and
the protein concentration was determined using the BCA kit (Bio-
Rad, Hercules, CA). Between 0.25 and 05 ug of protein, placed in
a 50-mL reaction mixture, was used for the TRAP assay. After
30 min of incubation at 30uC, 27 cycles of PCR amplification
were performed (30 min at 94uC followed by 30 min at 59uC).
The PCR products were then analyzed by electrophoresis on 10%
polyacrylamide non-denaturing gels. Gels were analyzed and
quantified using the PhosphorImaging system with Imagequant
software (Molecular Dynamics inc., Sunnyvale, CA). Each
experiment was performed twice.
Real-time RT-PCR for hTERT
Total RNA was isolated using the RNAqueous kit (Ambion,
Austin, TX) and further purified using the DNA-free kit (Ambion,
Austin, TX). The reverse transcription and PCR reactions were
performed using the TaqMan Gold one-step RT-PCR kit in the
ABI Prism 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA). Reverse transcription was carried out at 48uC for
30 min. The PCR conditions consisted of a 10-min step at 95uC
and 40 cycles between 95uC for 15 s and 65uC for 1 min. A
housekeeping control gene, acidic ribosomal phosphoprotein P0
(RPLP0, also known as 36B4), was used as an internal control to
correct for differences in the amount of RNA in each sample [25].
Primers and fluorogenic probes for hTERT and RPLP0 have been
described previously [25]. The standard curve for hTERT was
generated by using dilutions of a known amount of cRNA
synthesized by in vitro transcription of a cloned fragment. The
normalized level of hTERT in each sample was estimated by a
ratio of the hTERT level to the RPLP0 level, as described
previously [25]. Experiments were performed in duplicate and
repeated twice for consistency.
Western Blot Analysis
Ishikawa cells were plated at a density of 36105 cells/well in six-
well plates. After 24 hours, the medium was aspirated and
replaced with serum-free medium. After 24 hours, the cells were
treated with E2, UO126 or both in combination for a minimum of
15 min and a maximum of 24 hr. The plates were scraped with
RIPA buffer and cell lysates were prepared in 26SDS buffer. The
cell lysates were separated by 12% SDS-PAGE gel and transferred
onto a nitrocellulose membrane. The membrane was blocked for
1 hr in TBS-T +5% nonfat dry milk, and then incubated with
phosphophorylated-p44/42 MAPK monoclonal antibody (1:2000)
or pan-p44/42 MAPK polyclonal antibody (1:1000) overnight at
4uC (Cell Signaling, Beverly, MA). The membrane was then
washed in TBS-T and incubated with a secondary peroxidase-
conjugated antibody for 1 hr. Antibody binding was detected
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using an enhanced chemiluminescence detection system (ECL).
Band net intensities were quantified using a Millipore Digital
Bioimaging System (Bedford, MA). Each experiment was
performed twice.
In Vitro Kinase Assay
Activity of p44/42 kinase activity was measured in vitro using the
p44/42 MAP kinase assay kit (Cell Signaling, Danvers, MA).
Briefly, Ishikawa cells were plated at a density of 36105 cells/well
in six-well plates. Following E2 and UO126 treatment, plates were
washed 4 times with ice-cold PBS, and 0.5 mL ice-cold lysis buffer
+1 mM PMSF was added to each well. Cells were scraped,
sonicated, and centrifuged at 10,000 g for 10 min at 4uC. The
resulting supernatent was incubated with 15 uL of resuspended
immobilized phospho-p44/42 MAP kinase (Thr202/Tyr204)
monoclonal antibody for 12 hr at 4uC. The immune complex
was washed with lysis buffer 5 times and once with kinase buffer
without substrate. Immunoprecipitated MAPK was then incubat-
ed for 30 min at 30uC in kinase buffer with 2 ug Elk1 fusion
protein and 200 uM ATP. The kinase reaction was stopped by
adding 25 ul of 36 SDS buffer. ElK1 was separated by SDS-
PAGE gel, and was then incubated with anti-phospho-Elk1 (Ser
308) antibody at 4uC overnight. Elk1 was detected with ECL as
described for western blot analysis. Each experiment was
performed twice.
Luciferase assay
Transient transfection of luciferase reporter plasmids was
performed using the TransFast Transfection Reagent (Promega,
Madison, WI). Briefly, 86104 of Ishikawa cells were seeded in 24-
well plates overnight and transfected with promoter luciferase
plasmids (0.5 mg/well). The pRL-SV40 (2 ng/well) containing
Renilla reniformis luciferase was co-transfected in each transfec-
tion as an internal control to normalize the transcriptional
Figure 1. The effect of E2 on telomerase activity and hTERT expression in the ER-positive Ishikawa cell line. Cells were treated with
different concentrations of E2 (0.1–10 mM) for 48 hr or treated with 1 uM E2 in a time-course fashion (A). Telomerase activity was determined by the
TRAP assay. hTERT RNA expression was assessed by real-time RT-PCR (B). The data are presented as means 6 SD of duplicated samples from at least
two independent experiments. (ITAS = internal telomerase assay standard, C = control).
doi:10.1371/journal.pone.0055730.g001
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activity of the hTERT promoter plasmids. The luciferase assay
was then performed using the Dual Luciferase Reporter Assay
System (Promega, Madison, WI) according to protocols provided
by the manufacturer. All experiments were performed in
triplicate for each plasmid, and each experiment was performed
twice.
ERK 1/2 siRNA assay
ERK 1/2 small interfering RNA (siRNA) was purchased from
Cell Signaling Technology (Danvers, MA). According to the
manufacturer’s instructions, Ishikawa cells were plated in 6-well
plates or 12-well plates at the recommended cell concentration.
After 24 hours, transfections were performed at approximately
60% confluency using transfection reagent (Santa Cruz Biotech-
nology, Santa Cruz, CA). For each transfection reaction, 100 nM
ERK 1/2 siRNA or control siRNA was used for preparation of
siRNA-transfection complexes at room temperature for 15 min.
Transfections were performed in 0.5 (12-well plate) or 1.5 mL (6-
well plate) serum-free medium for 8 hr. After incubation,
transfection complexes were removed and replaced with their
corresponding media. In each experiment, untreated controls
receiving transfection reagent were included. Transfection effi-
ciency (80%–90%) was determined by fluorescence microscope in
fluorescein-labeled nonspecific siRNA transfected cells and by
Western blotting analysis. Cells were utilized for Western blotting
analysis, TRAP assay, lucifersae activity and real time PCR at 36–
48 hr after transfection.
Results
The effect of E2 on hTERT mRNA and telomerase activity
in Ishikawa cells
In the Ishikawa cell line, E2 was found to increase telomerase
activity in a dose-dependent manner as assessed by TRAP assay
(Figure 1A). The increased activity was dependent on both E2
concentration and length of time of exposure. When 0.1–10 mM of
E2 was added, telomerase activity was up-regulated at 12 hr,
which persisted until at least 72 hr following treatment. Treating
cells with 1–10 mM of E2 for more than 48 hr induced maximal
telomerase activity. No effect of E2 on telomerase activity was
detected in the ERa negative endometrial cancer cell line (HEC-
1B), under the same treatment conditions (data not shown).
To understand the underlying mechanism of induction of
telomerase activity, we quantified by real-time RT-PCR assay the
level of hTERT mRNA expression under the same conditions.
The hTERT gene encodes the catalytic subunit of telomerase and
is usually the rate-limiting determinant of telomerase enzymatic
Figure 2. The effect of UO126 on telomerase activity and hTERT mRNA expression. The Ishikawa cells were treated with UO126 at varying
concentrations (0.1–10 mM) for 24 hr. Telomerase activity was assessed by TRAP assay (A and B) hTERT expression was assessed by real time RT-PCR
(C). (C = control).
doi:10.1371/journal.pone.0055730.g002
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Figure 3. The effects of UO126 in combination with E2 on telomerase and hTERT mRNA expression in Ishikawa cells. Cells were
treated with 10 uM UO126 (U), 1 uM E2 or both in combination for 24 hr. (A) Telomerase activity was assessed by TRAP assay. (B) Telomerase activity
represented in graphical from using TPG (total product generated) which corresponds to relative telomerase activity. TPG is calculated from the ratio
of TRAP product band to the internal telomerase assay standard band. (C) hTERT mRNA expression was determined by real time RT-PCR. (C = control).
doi:10.1371/journal.pone.0055730.g003
Figure 4. The effects of E2 and UO126 on phosphorylation of p42/44 and ERK1 kinase activity in Ishikawa cells. Cells were treated with
1 uM E2, 10 uM UO126 (U) or both in combination for a minimum of 15 min and a maximum of 24 hr. Phosphorylation of p42/44 was determined by
Western blotting analysis. MAPK activity was assessed by immunoprecipitation assay for Elk1. E2 induced phosphorylation of p42/44 (A) and MAPK
activity in a time-dependent fashion (D). UO126 inhibited phosphorylation of p42/44 and MAPK activity induced by E2 (B, C and E). (C = control).
doi:10.1371/journal.pone.0055730.g004
Estrogen Induction of Telomerase
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activity. E2 increased hTERT mRNA expression in a dose-
dependent manner (1–10 mM). This up-regulation of activity was
observed within 6 hr after E2 treatment, and maximal induction
of hTERT mRNA expression was observed at 48 hr. E2-induced
hTERT mRNA expression remained elevated for greater than
72 hr (Figure 1B). These findings suggest that the regulation of
telomerase activity by E2 may occur at the transcriptional level in
endometrial cancer cells.
The effect of UO126 on telomerase activity and hTERT
mRNA expression in Ishikawa cells
To address the role of the MAPK pathway in E2-induced
telomerase activity in Ishikawa cells, we initially assessed the ability
of UO126, a specific MEK1 and MEK2 inhibitor, to directly
inhibit telomerase activity. In the Ishikawa cells, UO126 inhibited
telomerase activity in a dose-dependent manner (0.1–10 mM) as
demonstrated by TRAP assay (Figure 2A and 2B). In parallel,
UO126 decreased hTERT mRNA expression in a dose-depen-
dent manner, as quantified by real-time RT-PCR (Figure 2C).
These results demonstrate that UO126 is sufficient to inhibit
telomerase activity and hTERT mRNA transcription in endome-
trial cancer cells.
The effect of UO126 on E2-induced telomerase activity
and hTERT mRNA expression in Ishikawa cells
To investigate the impact of UO126 on E2-induced telomerase
activity and hTERT mRNA expression, cells were treated with
10 mM of UO126, 1 mM of E2, or both in combination (10 mM
UO126+1 mM E2) for 24 hr, and telomerase activity and hTERT
expression was subsequently determined. As shown in Figure 3, E2
induced increased telomerase activity and hTERT mRNA
expression to approximately 2–3 fold that of controls, and these
stimulatory effects were nearly abolished in the presence of
UO126 (10 mM). These data suggest that the function of the MEK
inhibitor, UO126, occurs not only at the level of the telomerase
enzyme itself, but also at the transcriptional level of the hTERT
gene.
The effect of UO126 on E2-induced activation of p44/42
In order to assess the interaction between E2 and the MAPK
pathway, we used a phosphorylated-specific p44/42 MAPK
Figure 5. The effect of estrogen and UO126 on hTERT promoter activity. Schematic diagram of hTERT promoter luciferase plasmids showing
two ERE binding sites and core promoter (A). Ishikawa cells were transfected with hTERT promoter luciferase plasmids and luciferase activity was
assayed after exposure to 1 uM E2 or 10 uM UO126 (U) for 36 hr. The data are presented as means 6 SD of duplicated samples from at least two
independent experiments. (C = control).
doi:10.1371/journal.pone.0055730.g005
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Figure 6. The effects of ERK1/2-specific siRNA in combination with estrogen on telomerase, hTERT expression and hTERT promoter
activity in Ishikawa cells. The cells were either transfected with ERK1/2 siRNA or negative control (Neg) for 8 hr and then treated with 1 uM
estrogen for 36–48 hr. The effect of transfection with ERK 1/2-specfic siRNA on phosphorylation for p42/p44 induced by estrogen was assessed by
Estrogen Induction of Telomerase
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antibody to identify E2-induced tyrosine phosphorylation of these
kinases in the Ishikawa cell line. Under serum-starved conditions,
we observed a low basal level of tyrosine-phosphorylated forms of
p44/42. Following treatment with 1 mM E2, phosphorylation of
p44/42 was rapidly induced and reached maximal induction
30 min after treatment. The level of phosphorylation of p44/42
remained elevated for approximately 60 min (Figure 4A). The
total p44/42 MAPK protein level remained constant throughout
these experiments, as determined by using a non-phosphorylated
antibody to p44/42 for the same cell membranes. Incubation with
10 mM UO126 completely blocked E2-induced phosphorylation
of p44/42 (Figure 4B and 4C).
To confirm that the increased phosphorylation of p44/42
represented the enzymatic activity of the protein, we measured
p44/42 kinase activity via an immune complex kinase assay in
which Elk1 served as the substrate. The Elk1 transcription factor is
a well-known downstream target of p44/42 and considered a
marker of MAPK activity. We observed a measurable increase in
the activity of p44/42 after E2 stimulation, with a maximal peak at
30 min. The p44/42 kinase activity was proportional to the degree
of phosphorylation of p44/42. UO126 also decreased the p44/42
kinase activity induced by E2 (Figure 4D and 4E). These data
confirm a relationship between E2 signaling and the MAPK
pathway in the Ishikawa cell line.
The effect of E2 and UO126 on hTERT promoter activity
Based on our previous work in endometrial cancer cell lines [2],
the transcriptional activity of the hTERT promoter may be
mediated by ERa binding to EREs located on this promoter. The
regulatory promoter sequence of the hTERT gene contains two
putative EREs in the 59 flanking sequence: the distal one at
22777/22755 and the proximal one at 2979/2956 that
overlaps with an Sp1 binding site [16,17]. To determine if
UO126 is involved in regulating hTERT promoter activity
induced by E2, we performed a series of transient transfections
with luciferase reporter plasmids containing the varying lengths of
the 59 promoter region of the hTERT gene. In brief, the Ishikawa
cells were transfected with two ERE-responsive reporters, one of
which contained both ERE sites, and the other which contained
only the proximal ERE/Sp1 site (Figure 5A). As shown in
Figure 5B, E2 increased luciferase activity from both reporters to
approximately 2.5 to 3 fold that of the control. UO126 effectively
blocked luciferase activity from these reporters in the presence of
E2 (Figure 5B). These results suggest that the MAPK pathway is
involved in E2/ERa-activation of the EREs in the hTERT
promoter; and thus, this pathway may be critical in mediating
hTERT transcriptional activity induced by E2.
The effects of ERK1/2-specific siRNA in combination with
E2 on telomerase activity, hTERT expression and hTERT
promoter activity in Ishikawa cells
In order to verify the involvement of the MAPK pathway in the
E2 induction of telomerase activity, we examined the consequenc-
es of transfection with ERK 1/2-specific siRNA in combination
with E2 on telomerase activity, hTERT expression and hTERT
promoter activity in the Ishikawa cell line. ERK1/2-specific
siRNA reduced phosphorylation of p42/44 induced by estrogen at
48 hr, as determined by Western blotting analysis (Figure 6A). By
densitometric quantification normalized to control protein eIF4E,
E2 increased phosphorylation of p42/44 by 29%, and E2 in the
presence of ERK1/2 specific siRNA decreased phosphorylation of
p42/44 by 79%. Telomerase activity and hTERT expression were
assayed by TRAP assay and real time RT-PCR at 48 hr (Figure 6B
and 6C). Similar to treatment with U0126, E2 induced increased
telomerase activity and hTERT mRNA expression to approxi-
mately 2–3 fold that of controls, and these stimulatory effects were
nearly abolished in the presence of ERK 1/2-specific siRNA.
Lucifersae activity was assayed after cells were transfected with
ERK1/2 siRNA for 24 hr, followed by transfection with the
hTERT promoter luciferase plasmid (P3915) and then treatment
with 1 uM estrogen for 36 hr (Figure 6D). As found for UO126,
transfection with ERK 1/2-specific siRNA effectively blocked
luciferase activity from the P3915 promoter in the presence of E2.
These results provide further evidence of the inter-relationship
between the MAPK pathway and E2-mediated induction of
hTERT transcriptional activity.
Discussion
We have previously shown that E2 induces telomerase activity
and hTERT mRNA expression in ER-positive endometrial cancer
cell lines, potentially through binding of complexed estrogen with
ERa to EREs found within the hTERT promoter. In the present
study, we wanted to elicit the underlying molecular mechanism
involved in regulating telomerase activity and hTERT mRNA
expression induced by E2 in the ERa-positive Ishikawa cell line.
Given the well-established relationship between ERa and the
MAPK pathway, it seemed logical that this pathway may be
involved in the induction of telomerase by E2.
Treatment with UO126, a highly selective inhibitor of both
MEK1 and MEK2, inhibited telomerase activity and hTERT
mRNA expression in the Ishikawa cells. In addition, U0126
completely blocked E2-stimulated telomerase activity and hTERT
Western blotting at 48 hr (Figure 6A). Telomerase activity and hTERT expression were assayed by TRAP assay and real time RT-PCR at 48 hr (Figure 6B
and 6C). Lucifersae activity was assayed after cells were transfected with ERK1/2 siRNA for 24 hr, followed by transfection with the hTERT promoter
luciferase plasmid (P3915) and then treatment with 1 uM estrogen for 36 hr (Figure 6D). (ITAS = internal telomerase assay standard, C = control).
doi:10.1371/journal.pone.0055730.g006
Figure 7. Proposed model of the interaction between E2 and
the MAPK pathway for the regulation of telomerase activity. In
essence, exposure to E2 leads to phosphorylation of p42/44 which is
necessary for hTERT mRNA expression. However, MAPK activation is
also critical for transactivation of the hTERT promoter by E2.
doi:10.1371/journal.pone.0055730.g007
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mRNA expression. Similar results were also found after transfec-
tion with ERK 1/2 –specific siRNA. Treatment with E2 resulted
in rapid phosphorylation of p44/42 MAPK and increased MAPK
functional activity, and this effect could be abolished by the
addition of UO126. Luciferase assays demonstrate that exposure
to UO126 or ERK 1/2-specific siRNA counteracted the
stimulatory effect of E2 treatment on EREs located in the hTERT
promoter. Thus, we provide evidence that E2 induces telomerase
activity and hTERT mRNA expression in ERa-positive endome-
trial cancer cells that is dependent on signaling through the MAPK
pathway. To our knowledge, only one other study has implicated a
cooperative role for MAPK in the regulation of hTERT with the
ER, and this was specifically for ERb in human pancreatic cell
lines [26].
A variety of studies have shown that the response of target genes
to estrogen depends on several important factors including the
nature of the estrogen receptor, the ligand and cell context, target
gene promoter and specific transcriptional factors, as well as agents
affecting protein kinase activation and protein phosphorylation
[2,16,27–29]. The human hTERT promoter contains an imper-
fect estrogen response element (ERE) and an ERE/Sp1 half site.
We and others have found that estrogen-induced hTERT gene
expression and telomerase activity may result from the direct
binding of ERa to two ERE sites located in the promoter region of
the hTERT gene [2,15–17]. In addition to EREs, this region
possesses consensus sequences for the binding of transcription
factors such as Sp1, Ap2, Ap4, c-Myc, NF-1 and E-box [8,29–31].
It has been demonstrated that E2 activation of the core hTERT
promoter can be completely eliminated when the c-Myc sites are
abrogated by mutations [16]. E2 has also been found to
significantly activate the c-Myc promoter in luciferase assays
using c-Myc promoter-reporter plasmids [16]. Based on this
culminated evidence, it can be postulated that estrogen may
mediate hTERT transcriptional activity through ERa directly
binding EREs in the hTERT promoter or alternatively, by E2-
activation of transcription factors that interact with this promoter,
or most likely via a combination of both mechanisms.
The MAPK signaling cascade regulates a variety of cellular
activities, including cell growth, differentiation, survival and cell
death. This pathway is thought to be essential in the regulation of
ERa transcription, including a novel mechanism by which ERa
and ERK2 co-localize at chromatin binding sites and collaborate
in the regulation of hormone stimulation of proliferation [32,33].
Estrogen receptor signaling and activation of the MAPK pathway
have also been implicated in the development and progression of
hormonally-driven cancers, such as breast and endometrial
cancer. Progesterone has been found to inhibit the estrogen-
induced activation of telomerase activity in breast and endometrial
cancer cell lines [34], and the MAPK pathway was demonstrated
to be partially responsible for this antagonistic effect. Tamoxifen, a
common adjuvant therapy for breast cancer, has estrogen-like
properties in uterine tissue and is associated with an increased risk
of endometrial cancer. Treatment of endometrial cancer cells with
tamoxifen has been shown to lead to the induction of telomerase
activity which could be effectively blocked by a MEK inhibitor.
Sp1 binding sites and ETS family member motifs have been found
in the hTERT promoter 59-flanking sequence [30,35–37], and
these represent potential transcription factors that are targeted by
the MAPK pathway and may be induced through estrogen and
progesterone signaling. MAPK cascade-mediated histone phos-
phorylation has also been implicated in transcriptional activation
of the hTERT gene in normal and malignant cells [38]. Our work
provides further evidence of the link between the MAPK pathway
and hormonal regulation of hTERT gene transcription.
Although UO126 and ERK 1/2 siRNA were both very effective
in blocking E2-induced telomerase activity and hTERT mRNA,
some residual activity did remain. This suggests that cell signaling
pathways other than the MAPK pathway may play a role in E2-
regulation of telomerase, such as the PI3K/Akt/mTOR pathway.
In ovarian cancer cell lines, E2 has been found to stimulate
telomerase activity via two mechanisms – transcriptional regula-
tion of hTERT via an ERE-dependent mechanism and the PI3K/
Akt/mTOR cascade as well as post-translational regulation
through Akt-dependent phosphorylation of hTERT [15]. Thus,
in parallel to E2’s complex effects on proliferation of the
endometrium, the interplay of E2 on telomerase activity may also
involve multiple signaling cascades.
In summary, our data suggest that estrogen induces telomerase
activity at the hTERT transcriptional level in endometrial
carcinoma cells, and this effect is mediated via the interaction
between estrogen and the MAPK pathway. To our knowledge,
this is the first study to link estrogen regulation of telomerase
activity with signaling through the MAPK pathway. We speculate
that both the estrogen-ERa-system-mediated and the MAPK-
pathway–mediated regulation of telomerase activity may be
related through a positive feedback mechanism, as depicted in
the model found in Figure 7. Our findings support cross talk
between E2, the MAPK pathway and regulation of telomerase
activity. As shown in this model, exposure to E2 leads to
phosphorylation of p42/44 which is necessary for hTERT
expression. However, MAPK activation is also critical for
transactivation of the hTERT promoter by E2. Further studies
will be aimed at identifying the individual components of the
ERa/MAPK pathway as well as other pathways involved in the
regulation of telomerase activity. Ultimately, a better understand-
ing of the relationship between estrogen, MAPK signaling and
telomerease activity may lead to the development of novel
therapeutic and preventative strategies for endometrial cancer as
well as other hormonally-driven cancers.
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